A5051264691- Substance Abuse Treatment and Outcomes
- Opioid Use Disorder Treatment
- Prenatal Substance Exposure Effects
- Homelessness and Social Issues
- Schizophrenia research and treatment
- HIV, Drug Use, Sexual Risk
- Pharmaceutical Practices and Patient Outcomes
- Food Security and Health in Diverse Populations
- Palliative Care and End-of-Life Issues
- Pain Management and Placebo Effect
- Cannabis and Cannabinoid Research
- Community Health and Development
- Adolescent Sexual and Reproductive Health
- Cancer survivorship and care
- Medical and Biological Sciences
- Forensic Toxicology and Drug Analysis
- COVID-19 and Mental Health
- Child Nutrition and Water Access
- Child and Adolescent Psychosocial and Emotional Development
- Treatment of Major Depression
- Family Support in Illness
- Food Waste Reduction and Sustainability
- Optimism, Hope, and Well-being
- Telemedicine and Telehealth Implementation
- Grief, Bereavement, and Mental Health
Friends Research Institute
2015-2024
Johns Hopkins University
2023-2024
Behavioral Pharma (United States)
2023
Johns Hopkins Medicine
2023
University of North Carolina at Chapel Hill
2019-2022
University of Maryland, College Park
2016
National Institutes of Health
2016
Emmes (United States)
2016
New York University
2016
David H. Murdock Research Institute
2016
Background: Substance use, a leading cause of illness and death, is underidentified in medical practice. Objective: The Tobacco, Alcohol, Prescription medication, other use (TAPS) tool was developed to address the need for brief screening assessment instrument that includes all commonly used substances fits into clinical workflows. goal this study assess performance TAPS primary care patients. Design: Multisite study, conducted within National Drug Abuse Treatment Clinical Trials Network,...
Pathological gambling disorder and problem are addictive disorders with severe consequences for individuals, families, society. Knowledge about associations between childhood adverse experiences (i.e., physical, sexual, emotional abuse) pathology in adulthood is limited. Using data from the National Epidemiologic Survey on Alcohol Related Conditions (NESARC), lifetime status were tested. Strong bivariate found, which attenuated inclusion of clinical covariates. Adverse might be related to...
Buprenorphine, an effective treatment for opioid use disorder (OUD), remains underutilized in many U.S. jails and prisons. However, of non-prescribed (i.e., diverted) buprenorphine has been reported these settings. The current study examined experiences correctional community contexts. conducted face-to-face interviews with 300 adults OUD/opioid misuse recent incarceration, recruited Baltimore, MD, New York, NY (n = 150 each). Illicit/non-prescribed during incarceration was by 63%...
The objective of this study was to estimate the associations jail-initiated medication for opioid use disorder (MOUD) and patient navigation (PN) with (OUD) at 6 months post-release. Three randomized trials (combined N = 330) were combined assess whether MOUD (extended-release naltrexone or interim methadone) initiated prior release from jail without PN would reduce likelihood a DSM-5 diagnosis OUD post-release relative enhanced treatment-as-usual (ETAU). Across three studies, assignment...
Objective Illicitly manufactured fentanyl has largely replaced heroin throughout the United States. Characteristics of fentanyl-specific withdrawal are not well understood compared to traditional opioid withdrawal. This study examines severity among 2 cohorts participants who underwent identical morphine stabilization procedures before and after was introduced local drug market. Methods The Non-Fentanyl (n = 103) included testing positive for non-fentanyl opioids, Fentanyl 30) fentanyl. Both...
Despite the effectiveness and growing availability of treatment for opioid use disorder (OUD) with buprenorphine, many people OUD do not access services. This article describes rationale, methodological design, evolution, progress an ongoing clinical trial linkage strategies untreated OUD.